RecruitingNCT06259149

A Study of Initiation Timing of VTE Prevention After Colorectal Cancer Surgery

A Study of Initiation Timing of VTE Prevention After Colorectal Cancer Surgery: a Single-center, Prospective, Observational Cohort Study


Sponsor

RenJi Hospital

Enrollment

914 participants

Start Date

Feb 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This project intends to conduct a single-center, prospective, observational cohort study to explore the impact of the timing of drug prophylaxis on the risk of postoperative bleeding and the preventive effect of VTE in the prevention and management of postoperative venous thromboembolism (VTE) after colorectal cancer (CRC) surgery in Chinese population, and to determine its application and promotion value. The research results of this project can provide useful reference for optimizing the prevention and management of VTE after CRC operation.


Eligibility

Min Age: 18 YearsMax Age: 110 Years

Plain Language Summary

Simplified for easier understanding

This study is examining the best timing for starting blood clot prevention (anticoagulation) after surgery for colorectal cancer (cancer of the colon or rectum). Blood clots are a serious risk after major surgery, but starting anticoagulation too soon can increase bleeding risk. **You may be eligible if...** - You are older than 18 - You have been diagnosed with colorectal cancer and are scheduled for surgery (either laparoscopic or open) to remove it - Your surgery is expected to take more than 45 minutes and your expected survival after surgery is more than 6 months - You or your legal guardian can give written consent **You may NOT be eligible if...** - You have significantly impaired kidney or liver function - Your cancer is too advanced or cannot be fully removed - You have a known allergy to blood thinners (low molecular weight heparin) - You have a bleeding disorder, active ulcer, uncontrolled high blood pressure, or recent stroke or brain surgery - You had a blood clot in the past 3 months - You are currently on blood-thinning medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNardraparin calcium injection

The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day


Locations(1)

Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06259149


Related Trials